European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development

被引:0
作者
Timmerman, Philip [1 ]
Herling, Christian [1 ]
Stoellner, Daniela [1 ]
Jaitner, Birgit [1 ]
Pihl, Susanne [1 ]
Elsby, Karen [1 ]
Henderson, Neil [1 ]
Barroso, Begona [1 ]
Fischmann, Stephanie [1 ]
Companjen, Arjen [1 ]
Versteilen, Amanda [1 ]
Bates, Stewart [1 ]
Kingsley, Clare [1 ]
Kunz, Ulrich [1 ]
机构
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
关键词
LIGAND-BINDING ASSAYS; SURROGATE END-POINTS; VALIDATION;
D O I
10.4155/BIO.12.164
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Biomarkers have become increasingly important in drug development and many bioanalysts are getting involved. Consequently, different views on how to approach the bioanalysis of biomarkers have been published or are being developed. The European Bioanalysis Forum has intensively discussed this topic since 2010 and is ready with their recommendation on method establishment and bioanalysis of biomarkers. Acknowledging that the challenges step outside the bioanalytical laboratory is a cornerstone of our recommendation. The importance of integrating all scientific aspects, from purely analytical aspects, all the way to understanding the biology and effects of the biomarker, prior to embarking on method establishment or sample analysis, cannot be underestimated. Close and iterative interactions with the teams requesting the data is imperative to develop a bioanalytical strategy that combines science, analytical performance and regulations. The European Bioanalysis Forum developed a straightforward decision tree to help the scientific community in developing a bioanalytical strategy for any biomarker in drug development.
引用
收藏
页码:1883 / 1894
页数:12
相关论文
共 16 条
[1]  
Agencia Nacional de Vigilancia Sanitaria, 2003, GUID VAL AN BIOAN ME
[2]  
[Anonymous], CPMPICH28695
[3]  
[Anonymous], GUID IND QUAL PROC D
[4]  
[Anonymous], 2011, Science Medicines Health, Guideline on bioanalytical method validation.
[5]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[6]   Mechanism-based pharmacokinetic-pharmacodynamic modeling - A new classification of biomarkers [J].
Danhof, M ;
Alvan, G ;
Dahl, SG ;
Kuhlmann, J ;
Paintaud, G .
PHARMACEUTICAL RESEARCH, 2005, 22 (09) :1432-1437
[7]   Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules [J].
DeSilva, B ;
Smith, W ;
Weiner, R ;
Kelley, M ;
Smolec, JM ;
Lee, B ;
Khan, M ;
Tacey, R ;
Hill, H ;
Celniker, A .
PHARMACEUTICAL RESEARCH, 2003, 20 (11) :1885-1900
[8]  
Dijksman J, 2012, BIOANALYSIS, V4, P633, DOI [10.4155/BIO.12.36, 10.4155/bio.12.36]
[9]  
Food and Drug Administration (FDA) Guidance for Industry, 2008, SAF EFF PHAR STUD SU
[10]   Generic approach to validation of small-molecule LC-MS/MS biomarker assays [J].
Houghton, Richard ;
Pita, Catarina Horro ;
Ward, Ian ;
Macarthur, Roy .
BIOANALYSIS, 2009, 1 (08) :1365-1374